Alx Oncology Holdings (ALXO) Depreciation & Amortization (CF) (2019 - 2026)

Alx Oncology Holdings has disclosed Depreciation & Amortization (CF) across 8 years of filings, most recently posting $150000.0 for Q1 2026.

• Depreciation & Amortization (CF) for Q1 2026 came in at $150000.0, down 28.91% year-over-year; the trailing twelve-month figure through Mar 2026 was $645000.0 (down 25.78% YoY), and the FY2025 annual result was $706000.0, down 19.04% from the prior year.
• Depreciation & Amortization (CF) came in at $150000.0 for Q1 2026 at Alx Oncology Holdings, down from $151000.0 in the prior quarter.
• In the past five years, Depreciation & Amortization (CF) ranged from a high of $224000.0 in Q3 2024 to a low of $58000.0 in Q1 2022.
• The 5-year median for Depreciation & Amortization (CF) is $207000.0 (2023), against an average of $170941.2.
• Across the five-year window, Depreciation & Amortization (CF) soared 1483.33% in 2022 and sank 31.7% in 2025, its largest moves.
• Alx Oncology Holdings' Depreciation & Amortization (CF) stood at $105000.0 in 2022, then surged by 97.14% to $207000.0 in 2023, then grew by 3.38% to $214000.0 in 2024, then retreated by 29.44% to $151000.0 in 2025, then decreased by 0.66% to $150000.0 in 2026.
• The last three Depreciation & Amortization (CF) figures came in at $150000.0 (Q1 2026), $151000.0 (Q4 2025), and $153000.0 (Q3 2025), per Business Quant data.